The Business Year talks to Joe Henein, CEO of NewBridge Pharmaceuticals, on competitive advantages and future investments

  Since its foundation in 2010, what were some of the pivotal factors that have shaped the company up until this point? There are there key pivots that shaped our company and defined what we are today. Remember that NewBridge Pharmaceuticals is truly an innovative business model. It’s a free enterprise backed by investors, not [...]

NewBridge Pharmaceuticals Hosts a Conference on Genomic Testing to Bring Hope to Patients with Breast Cancer

Use of OncotypeDX® Changes Treatment Recommendations for Women With Hormone Receptor Positive, Her2 Negative Breast Cancer, Leading to Overall Reduction in Chemotherapy NewBridge Pharmaceuticals, the regional licensed representative for class-leading medical diagnostic solutions, held a press conference highlighting the latest advancements in genomic breast cancer screening methods on Monday, November 17th at Radisson Blu Hotel [...]

Bridging East and West for Biotech

Joe Henein, President & CEO of NewBridge Pharmaceuticals, talks about the evolution of the company since his joining, what makes NewBridge Pharmaceuticals a unique partner within the industry…    

NewBridge Pharmaceuticals Enters into a Partnership with Eisai to Market Breast Cancer Treatment Halaven® (ERIBULIN) in the Middle East region

NEWBRIDGE ANNOUNCES PARTNERSHIP WITH EISAI TO MARKET BREAST CANCER TREATMENT HALAVEN® (ERIBULIN) ACROSS THE MIDDLE EAST  Dubai, UAE, 18 November 2013 – Eisai announces today that Halaven® (eribulin) will be marketed in selected countries within the Middle East region through a new partnership between Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) and [...]

NewBridge Pharmaceuticals secures significant investment from Elan, boosting growth and expansion

Elan Corporation, plc. invests Series C financing in NewBridge Pharmaceuticals and becomes a major shareholder alongside Burrill & Company and Kuwait Life Sciences Company. Dubai, UAE: 29 May, 2013: NewBridge Pharmaceuticals  announced the close of a Series C equity fundraising from the Irish corporation, Elan, to expand its commercial and manufacturing operations in the Africa, Middle [...]